The company is set to release its quarterly earnings on Wednesday, April 29th, with a consensus estimate of $1.44 per share.
Bristol-Myers Squibb Company (BMY) is currently priced at $58.41, marking a 1.09% increase from the previous close. Trading volume is at $1.56 million, representing a 12.38% increase compared to the average.
In the latest earnings report on Wednesday, February 4th, the company exceeded expectations with an EPS of 1.35. The earnings call revealed positive developments, setting the stage for the upcoming report.
With a forward dividend yield of 4.31% and a dividend per share of 63 cents, Bristol-Myers Squibb maintains a strong financial stance, ensuring investor confidence.
The company showcases a healthy cash flow position, with free cash flow standing at $1.60 billion and a net change in cash of -$5.51 billion, reflecting strategic financial management.
Bristol-Myers Squibb reports a solid revenue of $12.50 billion and a net income of $1 billion, underlining consistent profitability and operational efficiency.
Key financial metrics demonstrate the company's strength, with notable ratios like return on equity at 5.88% and a price to earnings ratio of 25.34, indicating strong investor value.
The balance sheet reveals a robust financial position, with total assets at $90 billion and total liabilities at $71.53 billion, showcasing stability and growth potential.
This comprehensive overview indicates Bristol-Myers Squibb's resilience and strategic positioning in the market, setting a positive tone for its upcoming earnings report.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.